期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

对艾滋病抗逆转录病毒治疗成效的回顾 被引量：3

下载PDF
导出
摘要 2006年5月30日联合国艾滋病规划署公布了一份喜忧参半的报告：随着各国投资额增加、致力于AIDSI坊治人数的增加，AIDS流行25年来首次呈现新发感染及患者总数走缓趋势。高效抗逆转录病毒治疗（HAART）的覆盖面扩大是阻断母婴垂直传播，明显延长HIV感染者生存期的重要手段。
作者 王永怡
机构地区 <传染病信息>杂志社
出处 《传染病信息》 2007年第1期59-61,共3页 Infectious Disease Information
关键词 联合国艾滋病规划署 抗逆转录病毒治疗 HIV感染者 母婴垂直传播 AIDS 生存期
分类号 R512.91 [医药卫生—内科学]
  • 相关文献

参考文献16

  • 1Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less .AIDS Clinical Trials Group 320 Study Team[J]. N Engl J Med, 1997 ,337(11):725-733.
  • 2Staszewski S, Morales-Ramirez J, Tashima KT,et al.Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in aduhs.Study 006 Team [J].N Engl J Med, 1999,341 (25): 1865-1873.
  • 3Walmsley S, Bemstein B, King M, et al.Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection [J].N Engl J Med, 2002,346(26):2039-2046.
  • 4Robbins GK, De Gruttola V, Sharer RW, et al. Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection [J]. N Engl J Med, 2003,349(24):2293-2303.
  • 5Gallant JE, Staszewski S, Pozniak AL, et al.Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial [J].JAMA, 2004,292(2): 191-201.
  • 6Walensky RP, Paltiel AD, Losina E, et al. The survival benefits of AIDS treatment in the United States [J]. J Infect Dis,2006,194(1):11-19.
  • 7Gulick RM, Ribaudo H J, Shikuma CM, et al. Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection[J]. N Engl J Med,2004,350(18):1850-1861.
  • 8Finzi D, Blankson J, Silieiano JD, et al.Latent infection of CD4^+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy[J].Nat Med, 1999,5(5):512-517.
  • 9Deeks SG, Wrin T, Liegler T, et al. Virologic and immunologic consequences of discontinuing combination antirelroviral-drug therapy in HIV-infected patients with detectable viremia[J]. N Engl J Med, 2001,344(7):472-480.
  • 10Deeks SG, Hoh R, Neilands TB, et al.Interruption of treatment with individual therapeutic drug classes in adults with multidrug-resistant HIV-1 infection [J].J Infect Dis,2005,192(9):1537-1544.

二级参考文献19

  • 1Walensky RP, Paltiel AD, Losina E, et al. The survival benefits of AIDS treatment in the United States [J]. J Infect Dis, 2006, 194(1): 11-19.
  • 2Panel on Clinical Practices for Treatment of HIV Infection.Guidelines for the use of antiretroviral agents in HIV-l-infected adults and adolescents[C]. US Department of Health and Human Services, May 4, 2006.
  • 3Liz H.Outcomes in HIV-HBV coinfected patients treated with drugs active against both viruses[EB/OL].[2006-10-17].http://www.hivandhepatitis.com.
  • 4Leon A, Mallolas J, Martinez E, et al. High rate of virological failure in maintenance antiretroviral therapy with didanosine and tenofovir[J]. AIDS,2005, 19: 1695-1697.
  • 5Saag MS. Emtricitabine, a new antiretroviral agent with activity against HIV and hepatitis B virus[J]. Clin Infect Dis,2006,42:126-131.
  • 6Ribaudo HJ, Haas DW, Tierney C, et al. Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: an Adult AIDS Clinical Trials Group Study[J]. Clin Infect Dis,2006,42:401-407.
  • 7Sanne I, Mommeja-Marin H, Hinkle J, et al. Severe hepatotoxicity associated with nevirapine use in HIV-infected subjects[J]. J Infect Dis, 2005, 191: 825-829.
  • 8Vingerhoets J, Peeters M, Corbett C, et al. Effect of haseline resistance on the virologic response to a novel NNRTI TMC 125 in patients with extensive NNRTI and PI resistance analysis of study TMC 125-C223[C]. 13th Conference on Retroviruses and Opportunistic Infections. February 5-8, 2006; Denver, Colorado. Abstract 154.
  • 9Shelton MJ, Ford S, Anderson MT, et al. Overview of drug interactions between brecanavir (BCV) and other HIV protease inhibitors (PIs) [C]. 16th International AIDS Conference. August 13-18, 2006; Toronto, Canada. Abstract TUAB0105.
  • 10Grinsztejn B , Nguyen BY , Katlama C , et al. Potent antiretroviral effect of MK-0518, a novel HIV-1 integrase inhibitor in patients with triple class resistant virus[C]. 13th Conference on Retroviruses and Opportunistic Infections.February 5-8, 2006; Denver, Colorado. Abstract 159.

共引文献1

同被引文献9

  • 1王永怡.对艾滋病现状谈几点感触[J].传染病信息,2007,20(2):122-124. 被引量：5
  • 2李嘉华,李彤,庄辉.HIV-1侵入细胞抑制剂研究进展[J].传染病信息,2006,19(5):233-237. 被引量：2
  • 3郑伯健,赵秀英.重视天然免疫功能在防治HIV感染中的作用[J].传染病信息,2006,19(5):251-255. 被引量：2
  • 4王永怡,王六娣.AIDS防治实验研究的新动向[J].传染病信息,2007,20(3):182-184. 被引量：3
  • 5ZHANG JT. copparation of ginsenoside Rg1 and RB1 pharmaco-logic action, basic clin Med, 2000, 20: 388-390.
  • 6Jimenez - Baranda S. Gomez - Mouton C, Rojas A, et al. Filamin - A regulates aetin -dependent clustering of HIV receptors[J].Nat Cell Biol, 2007,9 ( 7 ) : 838 - 846
  • 7Munch J, Stondker L, Adermann K, et al. Discovery and optimization of a natural HIV - 1 entry inhibitor targeting the gp41 fusion peptide [J]. Cell, 2007,129(2) : 263 -275
  • 8Levine BL, Humeau LM, Boyer J,et al. Gene transfer in humans using a conditionally replicating lentiviral vector[J].Proc Natl Acad Sci U S A. 2006,103 (46) : 17372 - 17377
  • 9Sarkar I, Hauber I, Hauber J, et al. HIV - 1 proviral DNA excision using an evolved reeombinase[J].Science, 2007,316 ( 5833 ) : 1912 - 1915

引证文献3

二级引证文献2

传染病信息
2007年 第1期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部